Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Vaccine developer Novavax Inc. NASDAQ: NVAX stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious diseases, including COVID-19, influenza, respiratory syncytial and Ebola.

Is Novavax Finally Turning Things Around?

Novavax, Inc. (NASDAQ:NVAX ) BofA Securities 2023 Health Care Conference May 11, 2023 1:00 PM ET Company Participants John Jacobs - President & Chief Executive Officer Filip Dubovsky - President-Research and Development Conference Call Participants Alec Stranahan - Vice President & Senior Biotech Analyst Alec Stranahan Hey, everyone. Good afternoon and welcome to -- or I guess good morning.

Novavax, Inc. (NVAX) Presents at BofA Securities 2023 Health Care Conference

Novavax's John C. Jacobs detailed his plan to cut costs and manage cash flow.

Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too

GAITHERSBURG, Md. , May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ (NVX-CoV2373) into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.

Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore

Carvana

Fueling the flames of speculative fervor, business news agency CNBC released its list of the most heavily shorted public securities. Topping the list stood used-car retailer Carvana (NYSE: CVNA ).

Short-Squeeze Stocks Alert: CVNA, NVAX Make Most-Shorted Stocks List

Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.

Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View

Novavax is cutting costs and restructuring to stay afloat as vaccine demand declines. As part of that effort, the company plans on cutting 25% of its workforce.

Is the Worst Over for Novavax?

Intel

The layoffs are all at least in the hundreds, and cite difficult economic times as the reason.

Layoffs Misery Continues In Tech With LinkedIn, Intel And Novavax All Axing Roles

Paramount Global

More than 136,000 employees were laid off by major U.S. companies in the first quarter of 2023.

Spring 2023 Layoff Tracker: Paramount, Novavax, LinkedIn Cut Hundreds Of Employees

Novavax, Inc. (NASDAQ:NVAX ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Erika Schultz - Senior Director of IR John Jacob - President & Chief Executive Officer Filip Dubovsky - Chief Medical Officer John Trizzino - Chief Commercial Officer & Chief Business Officer James Kelly - Chief Financial Officer & Treasurer Conference Call Participants Roger Song - Jefferies Eric Joseph - JPMorgan Mayank Mamtani - B. Riley Operator Good morning, and welcome to Novavax First Quarter 2023 Financial Results and Operational Highlights Conference Call.

Novavax, Inc. (NVAX) Q1 2023 Earnings Call Transcript

Novavax Inc shares surged Tuesday after the COVID-19 vaccine producer announced plans to cut expenses that include a roughly 25% workforce reduction.  The company said it plans to slash next year's research and development costs, along with selling, general and administrative expenses, by 40% to 50%.

Novavax to cut 25% of its workforce as Covid-19 vaccine sales fall off; shares pop

The shares of Novavax Inc (NYSE:NVAX) are soaring today, up 47.9% at $11.02 at last glance, after a series of updates.

Novavax Soars on Promising Data, Job Cuts

Novavax is laying off 25% of its workforce to slash expenses, the biotech company said Tuesday.

Novavax says it is axing 25% of its workforce to cut costs

Spring 2023 Layoff Tracker: Novavax, LinkedIn Cut Hundreds Of Employees

Apple

Airbnb

Akamai Technologies

AMC Entertainment

Anheuser-Busch InBev

Blackstone Group

Colgate-Palmolive

Credit Suisse

Duolingo

GameStop

Hain Celestial Group

Harmonic

Lucid Group

Mullen Automotive

PacWest Bancorp

Palantir Technologies

Plug Power

PayPal

Rivian Automotive

Shoals Technologies Group

iShares 0-5 Year TIPS Bond ETF

Skyworks Solutions

Tempur Sealy International

Trevena

Friday's bullish session on Wall Street seems to have gone nowhere, save for the Nasdaq Composite COMP wriggling its way out of a bear market.

‘It's ridiculous.' Buy short-term Treasury bills because debt-ceiling deal will come, says bond legend Bill Gross

Novavax (NASDAQ: NVAX ) layoffs are on the way as the vaccine maker revealed plans to cut a large portion of its workforce on Tuesday! The company revealed that it intends to cut 25% of its global workforce to reduce operating costs.

Novavax Layoffs 2023: What to Know About the Latest NVAX Job Cuts

Novavax offered a better-than-expected sales outlook Tuesday and announced a 25% reduction in its workforce. In response, NVAX stock rose.

Novavax Offers Upbeat Sales Guide, But Scraps 25% Of Its Workforce

Novavax still reported bleak first-quarter earnings and revenue that missed Wall Street's estimates.

Novavax shares rise after company unveils positive vaccine data, plan to cut 25% of workforce

Novavax (NASDAQ: NVAX ) reported first quarter results for 2023 today. Novavax reported a loss per share of $3.41.

NVAX Stock Earnings: Novavax Beats EPS, Misses Revenue Estimates

The Covid-19 vaccine manufacturer is aiming to sharply reduce costs as it hopes to bring new shots to the market.

Novavax Plans to Cut 25% of Staff. Here's Why the Stock Is Rising.

Novavax Inc. NVAX reported positive results from three vaccine trials on Tuesday, one targeting both COVID and flu, one for stand-alone flu and one a high-dose COVID vaccine. All three candidates produced robust immune response in Phase 2 trials and showed a reassuring preliminary safety profile, said Novavax.

Novavax reports positive results in trial of 3 vaccines for flu and COVID, posts Q1 loss and plan to cut 25% of workforce

Announced global restructuring and cost reduction initiative with expected 2024 full-year R&D and SG&A reduction of approximately 40% to 50% vs 2022 Provided full year 2023 total revenue guidance of between $1.4 and $1.6 billion First quarter revenue reflects shift to seasonal demand pattern; on-track to deliver updated COVID vaccine for Fall season Announced positive Phase 2 topline results for COVID-Influenza Combination, standalone influenza, and high-dose COVID vaccine candidates Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.

Novavax Reports First Quarter 2023 Financial Results and Operational Highlights

This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID Preliminary topline immune responses for all three vaccine candidates were robust versus authorized comparators For the stand-alone influenza vaccine candidate, HAI responses were 31 to 56% higher for all four influenza strains compared to Fluad ® , and were 44 to 89% higher for A strains compared to Fluzone HD ® For the COVID-Influenza Combination vaccine candidate, anti-S IgG and neutralization responses achieved levels seen in Phase 3 trial with Novavax's prototype vaccine, with HAI responses generally consistent with Fluad ® and Fluzone HD ® All three vaccine candidates were well-tolerated and demonstrated a reassuring preliminary safety profile, with reactogenicity comparable to authorized comparators These Phase 2 results support continued development for all three vaccine candidates GAITHERSBURG, Md. , May 9, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its COVID-Influenza Combination (CIC), stand-alone influenza and high-dose COVID vaccine candidates all showed a reassuring preliminary safety profile as well as comparable reactogenicity to individual Novavax influenza and COVID vaccine candidates or authorized influenza vaccine comparators.

Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses

GAITHERSBURG, Md. , May 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the BofA Securities 2023 Health Care Conference.

Novavax to Participate in the BofA Securities 2023 Health Care Conference

GAITHERSBURG, Md. , May 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m.

News for Novavax Stock (NVAX)